Health Tech: Digital and Beyond | Heart Rhythm Society

Health Tech: Digital and Beyond

Content will explore the future of cardiovascular digital health through visionary, big conversations.

Content Stream Leads

Jennifer N. Avari Silva, MD, FHRS, CEPS-P

Jennifer N. Avari Silva, MD, FHRS, CEPS-P
@jenniferavari

Rod S. Passman, MD, FHRS

Rod S. Passman, MD, FHRS
@PassmanRod

Jeanne E. Poole, MD, FHRS, CCDS

Jeanne E. Poole, MD, FHRS, CCDS
@jepoolemd

Session Sneak Peek

Whose Data Is It Anyway?

Today, more than ever, human data is highly valued. Companies are acquired not on multiples of revenue but on multiples of the size of their data sets. For health data, there is even stricter regulation. Organizations that invest in the collection and storage of data may believe that the data belongs to them; people who are the source of the data may feel that the data is theirs and they deserve a return on its monetization. A data relationship between a medical device company, hospital, and patient may be even more complicated. Beyond the privacy concerns expressed around search and social media, there are new regulations such as the EU General Data Protection Regulation (GDPR) that argues that the right to privacy is fundamental, yet may complicate or hinder the ability to do large research at scale.

This session will aim to get to the core problem of who owns the data, touching on these aspects, and with perspectives from big tech/consumer companies, EHR vendors, medical device and remote monitoring companies, startups, and patients.

Moving Toward a Unifying Framework of Evidence Generation in Health Tech

This session will discuss the spectrum of evidence generation from device validation and pre-diagnostic clearance, indications-based approval for medical devices, and outcomes demonstration for recommendation and reimbursement. Common chasms and barriers on the road to progressive evidence generation and whether a unified framework is possible will be examined.

Virtual Clinical Trials Successes and Failures: How do we get to the next level?

Virtual trials were once touted as a panacea for all future trials, addressing issues of cost, efficiency, and scale. While there have been some major successes with virtual trials, others have failed to deliver. COVID could have been a strong spark for robust virtual trials, but it wasn’t. Participant engagement still remains the Achilles heel of app-based trials. This session will provide a critical look at virtual trials, examining recent successes and failures, addressing barriers and opportunities, and re-imagining how these trials should be conducted for the next decade. The session will also discuss how we can improve our trial machinery in the U.S. to prepare for the next global health crisis and discuss lessons learned from COVID.

Global Digital Divide: How Do We Narrow the Gap?

During this session, a panel will discuss the barriers to digital health virtual trials.

AI 101

A primer on AI will be followed by a panel discussion with audience participation.

Health Techquity — What Are We Doing Right?

TechQuity is the consideration, design, development, and implementation of technology solutions that promote, assure, and potentially enhance health equity. This session will examine issues pertaining to the digital divide, social determinants of health, and how to design for health equity – examining topical use cases on atrial fibrillation, heart failure, and COVID.

Focus on Atrial Fibrillation
  • The Scope of the Problem
    This brief primer will discuss the clinical importance of AF, global burden of AF, challenges in diagnosis and treatment, and pain points.
  • The Tech
    A rapid-fire overview of all the tech in the AF space, from AI for ECGs and ablation and risk prediction, to wearable and emerging technologies (ECG, PPG, facial video, ambient sensors, so much more), to RPM and care platforms for disease management and care delivery.
  • The Gaps
    This will build on the first two talks and discuss “crossing the chasm” - where we are stumbling, what is still needed, and how might we get there.
Group Chat: Can Health Tech Fix AFib?

This is a multidiscplinary discussion dedicated to discussing the challenges, opportunities, and paths forwards in developing, testing, deploying, and scaling health tech and digital solutions for detection and management of afib, as explored through the lens of patient, clinician, consumer tech, medtech, big tech, and other stakeholders. The panel will tackle a number of topics including the following:

  • What kind of tools do we need?
  • What data are actionable and how do we collect it?
  • Reliability of data—sensitivity/specificity
  • What are the gold standards? Do they need to be modified?
  • Can AI tell us the AF burden from technologies
  • Limitations of current state and current technologies—can they be addressed? Or technology is not yet mature?
  • Emerging technologies to get to the AF question (passive, inexpensive)
  • Can DH provide personalized care?
Altering The Trajectory Of Disease: From Early Signal Detection To Smarter, Smoother Disease Management
  • The State of Health Tech in Diabetes
  • The State of Health Tech in Hypertension
  • Industry Panel Discussion
    Recent studies indicate that health status begins to decline in the early 30s. The millenial generation, compared to Gen X, also has a higher age-adjusted prevalence of hypertension and diabetes. This session will focus on how to identify disease early and to deliver effective, ongoing sustainable care with digital health solutions. The session will also touch on risk factors mitigation for other downstream conditions such as atrial fibrillation (e.g. sleep apnea, HTN, obesity). The focus will include diabetes, hypertension, and achievement of healthy lifestyle factors. The panel can also address the following questions:
    • Employer facing programs work? Or is this just a free lunch perk?
    • How do you incentivize doctors to give asynchronous care in fee for service
    • Patient engagement and churn
Focus on Sudden Cardiac Death
  • The Scope of the Problem
    The global scope of the problem This brief primer will discuss the clinical importance of sudden cardiac death, global burden of SCD, challenges in diagnosis and treatment, and pain points.
  • The Tech
    This will be a rapid-fire overview of all the tech in the SCD space, from AI for risk prediction and treatment, to implantable defibrillators (and new versions on them), to wearable defibrillator technologies, and so much more.
  • The Gaps
    This will build on the first two talks and discuss the challenges and gaps and what is needed to address this.